Tirzepatide has not been studied in patients with a history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on tirzepatide.

Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.1

In a pool of two tirzepatide clinical trials for weight reduction (SURMOUNT-1 and SURMOUNT-2), 0.2% of tirzepatide-treated patients had acute pancreatitis confirmed by adjudication (0.14 patients per 100 years of exposure) versus 0.2% of placebo-treated patients (0.15 patients per 100 years of exposure).1

After initiation of tirzepatide, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting).1

If pancreatitis is suspected,

• discontinue tirzepatide, and
• initiate appropriate management.1

Continuation of tirzepatide after a confirmed diagnosis of pancreatitis should be individually determined in the clinical judgment of a patient’s health care provider.1

Eli Lilly and Company cannot provide treatment recommendations on the use of tirzepatide in patients with a history of pancreatic cysts. In formulating an assessment and approach, the health care practitioner may consider

• the information provided
• the patient’s prior medical history and concomitant medications, and
• other individual factors.

The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.